Stifel lowered the firm’s price target on Elanco (ELAN) to $18 from $20 and keeps a Buy rating on the shares. The firm’s thesis remains that in 2026 and beyond, EBITDA growth will outstrip revenue growth and EPS will grow faster than EBITDA, telling investors that Elanco “offers the best risk/reward among our Animal Health names.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco initiated with a Buy at UBS
- Elanco initiated with a Market Perform at Leerink
- Class Action Lawsuit Against Elanco Animal Health Inc. (NYSE:ELAN)
- Elanco acquires contract manufacturing facility in Speke, UK
- Elanco Animal Health Strengthens Board with New Appointment